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The arenavirus envelope glycoprotein (GPC) initiates infection in the host cell through pH-induced fusion
of the viral and endosomal membranes. As in other class I viral fusion proteins, this process proceeds through
a structural reorganization in GPC in which the ectodomain of the transmembrane fusion subunit (G2)
engages the host cell membrane and subsequently refolds to form a highly stable six-helix bundle structure that
brings the two membranes into apposition for fusion. Here, we describe a G2-directed monoclonal antibody,
F100G5, that prevents membrane fusion by binding to an intermediate form of the protein on the fusion
pathway. Inhibition of syncytium formation requires that F100G5 be present concomitant with exposure of
GPC to acidic pH. We show that F100G5 recognizes neither the six-helix bundle nor the larger trimer-of-
hairpins structure in the postfusion form of G2. Rather, Western blot analysis using recombinant proteins and
a panel of alanine-scanning GPC mutants revealed that F100G5 binding is dependent on an invariant lysine
residue (K283) near the N terminus of G2, in the so-called fusion peptide that inserts into the host cell
membrane during the fusion process. The F100G5 epitope is located in the internal segment of the bipartite
GPC fusion peptide, which also contains four conserved cysteine residues, raising the possibility that this
fusion peptide may be highly structured. Collectively, our studies indicate that F100G5 identifies an on-path
intermediate form of GPC. Binding to the transiently exposed fusion peptide may interfere with G2 insertion
into the host cell membrane. Strategies to effectively target fusion peptide function in the endosome may lead
to novel classes of antiviral agents.
Enveloped viruses enter their target cells through fusion of
the virus and cell membranes, in a process promoted by the
viral envelope glycoprotein. For some viruses, such as human
immunodeficiency virus (HIV), entry is initiated by interaction
of the envelope glycoprotein with cell surface receptor pro-
teins. Other viruses, such as influenza virus, are endocytosed
and membrane fusion is triggered by exposure to acidic pH in
the maturing endosome. The subsequent merger of the viral
and cell membranes is accomplished through a major struc-
tural reorganization of the envelope glycoprotein. Antiviral
strategies that target virus entry by using neutralizing antibod-
ies or small-molecule fusion inhibitors can, in many cases,
prevent virus infection and disease.
The Arenaviridae comprise a diverse group of rodent-borne
viruses, some of which are responsible for severe hemorrhagic
fevers in humans. Lassa fever virus (LASV) is endemic in
western Africa (59), and at least five New World species are
recognized to cause fatal disease in the Americas, including the
Argentine hemorrhagic fever virus Junín (JUNV) (63). New
pathogenic arenavirus species continue to emerge from their
distinct animal reservoirs (1, 11, 24). At present, there are no
licensed vaccines or effective therapies to address the threat of
arenavirus infection.
Arenaviruses are enveloped, negative-strand RNA viruses
whose bipartite genome encodes ambisense expression of four
viral proteins (12, 22). The arenavirus envelope glycoprotein,
GPC, is a member of the class I virus fusion proteins (33, 40,
75), a group that includes HIV Env, influenza virus hemagglu-
tinin (HA), and paramyxovirus F protein. These envelope glyco-
proteins share several salient features. The precursor glycopro-
teins assemble as trimeric complexes and are subsequently
rendered competent for membrane fusion by a proteolytic
cleavage that results in the formation of the mature receptor-
binding and transmembrane fusion subunits. The GPC precur-
sor glycoprotein is cleaved by the cellular SKI-1/S1P protease
(6, 51, 54) to generate the respective G1 and G2 subunits,
which remain noncovalently associated. The ectodomain of the
class I fusion subunit is distinguished by the presence of two
4-3 heptad repeat (HR1 and HR2) sequences that, in the
course of membrane fusion, refold to form the now-classical
six-helix bundle structure, which defines this class of envelope
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glycoproteins. Unlike other class I fusion proteins, GPC also
contains a cleaved and stable signal peptide (SSP) as a third
and essential subunit in the mature complex (2, 32, 69, 77, 81).
Arenavirus infection is initiated by G1 binding to a cell
surface receptor. The pathogenic clade B New World arena-
viruses utilize transferrin receptor 1 (TfR1) for entry (1, 64,
65), whereas those in clades A and C, as well as the Old World
viruses, bind -dystroglycan and/or an unknown receptor (15,
34, 71). The virion particle is subsequently endocytosed (9),
and membrane fusion is initiated by acidification in the ma-
turing endosome (17, 28, 29). pH-dependent activation of GPC
is modulated through a unique interaction between SSP and
G2 (79, 80) and can be targeted by small-molecule inhibitors
that block membrane fusion (76) and protect against arenavi-
rus infection (8, 52).
A generally accepted model for membrane fusion by the
class I envelope glycoproteins (reviewed in references 45 and
73) posits that the native complex exists in a metastable state
that is established on proteolytic maturation of the biosynthetic
precursor. Upon activation, whether by acidic pH in the endo-
some or receptor binding at the plasma membrane, the fusion
subunit that was sequestered in the prefusion state is exposed
and undergoes a series of dramatic conformational changes
leading to membrane fusion. In this process, a hydrophobic
region at or near the N terminus of the fusion subunit (the
fusion peptide) inserts into the host cell membrane, thus al-
lowing the protein to bridge the two membranes. This so-called
prehairpin intermediate subsequently collapses upon itself to
form the highly stable six-helix bundle structure, in which the
three HR2 helices pack into hydrophobic grooves on the tri-
meric HR1 coiled-coil in an antiparallel manner, bringing the
virus and cell membranes into apposition. Free energy made
available in the formation of this stable structure is thought to
drive fusion of the lipid bilayers. Peptides that correspond in
sequence to HR2 (C-peptides) bind to the putative prehairpin
intermediate and interfere with its refolding, thereby prevent-
ing membrane fusion (18, 57, 74). While the structure of the
six-helix bundle core has been elucidated in atomic detail (45,
73), information regarding the molecular pathway leading to
this postfusion state is largely indirect. Indeed, the prehairpin
intermediate is conceptualized through the activity of C-pep-
tide fusion inhibitors (57, 74).
In this report, we describe a G2-directed monoclonal anti-
body (MAb), F100G5, that recognizes a pH-induced interme-
diate of JUNV GPC and prevents GPC-mediated membrane
fusion. This MAb binds at or near the internal fusion peptide
of G2 and may act by interfering with its penetration into the
host cell membrane. These studies highlight the feasibility of
targeting short-lived GPC intermediates for inhibition of mem-
brane fusion.
MATERIALS AND METHODS
Monoclonal antibodies. For immunization, the G2 ectodomain sequences of
JUNV (Romero strain, amino acids 255 to 417; GenBank accession number
AY619641) and Machupo virus (MACV; Carvallo strain; amino acids 266 to 428;
GenBank accession number AY619643) were molecularly cloned into the
pQE30 Escherichia coli expression plasmid (Qiagen) The 6His-tagged fusion
proteins were expressed and solubilized in QIAexpress buffers containing 8 M
urea or 6 M guanidium hydrochloride (GdmHCl), bound to an Ni-nitrilotriacetic
acid (NTA) matrix (Qiagen), and eluted using a low-pH buffer (buffer E; Qiagen)
containing urea and 120 mM imidazole. Proteins were dialyzed against phos-
phate-buffered saline (PBS) and formulated with complete Freund’s adjuvant for
immunization. The antibody response in BALB/c mice was assessed in an en-
zyme-linked immunosorbent assay (ELISA) using the protein (60 ng per well) as
antigen (43), and spleens from responding animals were used to generate hy-
bridomas as previously described (5). Identification and purification of reactive
hybridomas were guided by ELISA using the respective immunogens. Hybrid-
oma cell culture supernatant was used as the source of MAb, and F100G5-
containing supernatant was estimated to contain 150 g/ml of immunoglobulin.
The well-characterized G1-directed MAb GB03-BE08 (68) and the JUNV nu-
cleoprotein-directed MAb NA05-AG12 were obtained from the CDC through
the NIH Biodefense and Emerging Infectious Diseases Research Resources
Repository.
Reactivity of the newly developed MAbs to authentic JUNV GPC was deter-
mined by Western blot analysis using Vero cell cultures infected with the Ro-
mero strain of JUNV. All virus experiments were performed in the biosafety
level 4 (BSL4) facility at the National Microbiology Laboratory of the Public
Health Agency of Canada (Winnipeg, Manitoba, Canada), and cell lysates were
boiled in sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
(PAGE) sample buffer prior to removal from containment. Proteins were re-
solved by SDS-PAGE, and Western blot reactivity was visualized by chemilumi-
nescence. The attenuated vaccine strain of JUNV, Candid 1 (4, 58), was grown
under BSL2 conditions at The University of Montana.
Dissection of the G2 six-helix bundle. JUNV G2 ectodomain segments (resi-
dues 264 to 414 and 305 to 418; referred to as G2-151 and G2-114, respectively)
were introduced into the pET3a vector (Novagen) and the recombinant proteins
were expressed in E. coli BL21(DE3)/pLysS (Novagen) as previously described
(57). Inclusion bodies were washed extensively with 1% Triton X-100 and solu-
bilized in buffer containing 8 M urea. The protein was then loaded onto a
DEAE-Sepharose column (Pharmacia) equilibrated with 3 M urea and eluted
using a NaCl gradient (0 to 1,000 mM). Following dialysis against 5% (vol/vol)
acetic acid, the protein was purified to homogeneity by reverse-phase high-
performance liquid chromatography (HPLC; Waters) on a Vydac C4 preparative
column (Hesperia, CA) with a water-acetonitrile gradient in the presence of
0.1% trifluoroacetic acid as previously described (70). Intramolecular disulfide
bonds were formed by air oxidation in the presence of 6 M GdmHCl, and the
oxidized protein was repurified by reverse-phase HPLC and lyophilized.
The G2-151 protein is largely aggregated in 50 mM Tris-HCl (pH 8.0) and was
resuspended in this buffer for digestion with trypsin or proteinase K (1:200,
wt/wt) for 1 h at room temperature as previously described (57). Soluble pro-
tease-resistant material was reduced with dithiothreitol, analyzed by reverse-
phase HPLC on a Vydac C18 column, and identified by N-terminal sequencing
and electrospray mass spectrometry (PerSeptive Biosystems Voyager Elite
[Cambridge, MA]). Additional peptides were synthesized by standard fluorenyl-
methoxycarbonyl chemistry with an acetylated N terminus and amidated C ter-
minus. After cleavage from the resin, the peptides were purified by reverse-phase
HPLC. Protein concentrations were determined by using the method of Edel-
hoch (31).
Circular dichroism spectroscopy. Circular dichroism (CD) experiments were
performed on an Aviv 62A/DS spectropolarimeter (Aviv Associates, Lakewood,
NJ) equipped with a thermoelectric temperature control, in phosphate-buffered
saline (PBS; 50 mM sodium phosphate, 150 mM NaCl; pH 7.0). CD spectra were
collected from 260 to 200 nm at 4°C, using an average time of 5 s and a
bandwidth of 1 nm. A []222 value of 33,000 deg cm2 dmol1 was taken to
correspond to 100% helix (21). Thermal stability was determined by monitoring
the ellipticity at 222 nm of the N29/C30 complex, []222, as a function of tem-
perature in PBS (pH 7.0). Thermal melts were performed in 2° intervals with a
2-min equilibration at the desired temperature and an integration time of 30 s.
Reversibility was verified by repeated scans. Superimposable folding and unfold-
ing curves were observed, and 85% of the signal was regained upon cooling.
Values of midpoint unfolding transitions (Tm) were estimated by evaluating the
maximum of the first derivative of []222 versus temperature (14).
Sedimentation equilibrium analysis. Analytical ultracentrifugation measure-
ments were carried out on a Beckman XL-A (Beckman Coulter) analytical
ultracentrifuge equipped with an An-60 Ti rotor (Beckman Coulter) at 20°C.
Peptide samples were dialyzed overnight against PBS, loaded at initial concen-
trations of 30, 100, and 300 M, and analyzed at rotor speeds of 22 and 25 krpm.
Data were acquired at two wavelengths per rotor speed setting and processed
simultaneously with a nonlinear least-squares fitting routine (47). Solvent density
and protein partial specific volume were calculated according to solvent and
protein composition, respectively (53). The apparent molecular mass of the
N29/C30 complex was within 10% of that calculated for an ideal trimer, with no
systematic deviation of the residuals.
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Peptide ELISA. Ninety-six-well microtiter plates (Immulon II; Thermo-
Labsystems) were coated overnight with purified peptide (10 g/ml in 50 mM
Tris-HCl, pH 8.8) and subsequently washed with Dulbecco’s phosphate-buffered
saline (DPBS) containing 0.1% Tween 20 and blocked in the same buffer plus 1%
bovine serum albumin and 5% dried milk. Control wells were coated with
S-protein (Novagen). Purified MAb (200 ng/well) or hybridoma supernatant
(undiluted or 1:4 dilution) in blocking buffer was incubated for 1 h at 37°C prior
to washing and incubation with a horseradish peroxidase-conjugated goat anti-
mouse secondary antibody (Jackson ImmunoResearch). Reaction of the Sure-
Blue TMB chromogenic reagent (KPL, Inc.) was stopped with the addition of 1
N HCl, and color was read at 450 nm. In our studies, specific binding was either
all or none: 2 absorbance units or 0.05 absorbance units.
GPC-mediated cell-cell fusion. The ability of MAbs to inhibit GPC-mediated
membrane fusion in cell culture was determined using the molecularly cloned
GPC from the MC2 strain of JUNV (GenBank accession number D10072) (79,
81). This GPC is closely related to that of the Romero strain and identical in its
G2 ectodomain. Transient expression was accomplished as previously described
(79, 81) using the bacteriophage T7 promoter in the pcDNA3.1-based (Invitro-
gen) GPC plasmid and Vero cells infected with the vTF-7 vaccinia virus express-
ing T7 polymerase (38). In some studies, to obviate potential concerns regarding
the relative efficiency of signal peptidase cleavage, GPC expression was accom-
plished by cotransfection of two plasmids: one expressing SSP (in which a stop
codon was introduced following the C-terminal amino acid in SSP [T58]) and the
other expressing the entire G1-G2 precursor (where SSP was replaced by the
conventional signal peptide of CD4) (78). The respective polypeptides have been
shown to associate in trans to reconstitute the native GPC complex (32, 80).
pH-dependent membrane fusion and syncytium formation were assessed using
a vaccinia virus-based -galactosidase fusion-reporter assay (62) as previously
described (80, 81). Briefly, Vero cells expressing GPC and the T7 polymerase
were gently sedimented onto, and cocultured for 3 h with, target cells infected
with the vCB21R-lacZ vaccinia virus bearing the -galactosidase gene under the
control of a T7 promoter (62). Syncytium formation was initiated by exposing the
coculture for 20 min to low-pH medium containing 10 mM HEPES and 10 mM
piperazine-N,N-bis(2-ethanesulfonic acid) (adjusted to pH 5.0) (80, 81). Cell-
cell fusion was reported based on expression of -galactosidase after a 5-h
incubation at neutral pH. Membrane fusion per se is likely completed during
exposure to acidic pH, as would occur in the endosome, and in this assay
becomes manifest only in the subsequent incubation period. -Galactosidase
activity was quantitated using the chemiluminescent GalactoLite Plus substrate
(Applied Biosystems) and a Tropix TR717 microplate luminometer. In studies
examining inhibition of cell-cell fusion, MAbs were added either to GPC-ex-
pressing cells prior to plating onto the vCB21R-lacZ target cells and throughout
the 3-h coculture, with a 20-min exposure to pH 5.0, or for the final 5-h incu-
bation at neutral pH. All incubations were at 37°C, and any residual buffering or
MAb carried over during medium changes are insignificant. MAb F100G5 su-
pernatant was used at a final concentration of 15 g/ml, and purified GB03-
BE08 was used at 10 g/ml.
Flow cytometry. Vero cells expressing GPC were resuspended in growth me-
dium, or in medium adjusted to pH 5.0, and incubated with intermittent swirling
for 10 min at 37°C. Cells were rapidly neutralized by the addition of ice-cold
DPBS containing 2% fetal bovine serum (FBS), collected by centrifugation, and
resuspended in buffer containing MAb (30 g/ml F100G5 or 10 g/ml GB03-
BE08) and 0.01% sodium azide. Note that GPC is irreversibly inactivated by
transient exposure to acidic pH in the absence of target cells and, at this point in
the assay, is no longer able to mediate membrane fusion (reference 29 and
unpublished data). After 1 h on ice, the cells were washed and incubated with a
fluorescein-conjugated goat anti-mouse secondary antibody and propidium diio-
dide prior to fixation using 4% formaldehyde. Populations were analyzed using
a FACSCalibur flow cytometer and CellQuest software (BD Biosciences) as
previously described (75). In some studies, GPC-expressing Vero cells were
treated at neutral pH with 50 M small-molecule fusion inhibitor ST-294 (8)
prior to acidification and subsequent incubation with MAb (76). ST-294 was
kindly provided by Sean Amberg (SIGA Technologies, Inc.).
Dissection of MAb epitopes. The G2 ectodomain region of the molecularly
cloned JUNV GPC (amino acids 252 to 424) was appended in frame to the C
terminus of maltose-binding protein (MBP) in the pMAL-c2E vector (New
England Biolabs) using standard PCR and molecular cloning techniques. Ex-
pression in E. coli TB1 cells (New England Biolabs) was induced by the addition
of isopropylthiogalactoside (ITPG), and cells were disrupted using Bugbuster
(Pierce) containing 250 units/ml Benzonase (Pierce) and protease inhibitors
(leupeptin, pepstatin, aprotinin, and phenylmethylsulfonyl fluoride). Aliquots of
the cleared lysate were incubated with a 50% slurry of amylose resin (New
England BioLabs) for 2 h at 4°C to purify the MBP fusion proteins. The resin was
subsequently washed, and bound fusion proteins were eluted with maltose. Pro-
teins were resolved using 4-to-12% NuPAGE bis-Tris gels (Invitrogen) and
detected by SYPRO Red protein stain (Molecular Probes) or by Western blot
analysis. N- and C-terminal portions of the G2 ectodomain (amino acids 252 to
316 and 317 to 424, respectively) were similarly appended to MBP for analysis.
GPC mutants were used to further dissect MAb-binding epitopes. GPC mu-
tants were created using QuikChange mutagenesis (Stratagene), replacing highly
conserved charged residues in the N-terminal portion of G2 with alanine. These
mutants (D260A, K283A, K292A, H297A, E300A, D303A, R306A, D309A,
D339A, K344A, R348A, and K360A) were characterized as previously described
(79) and used in Western blot experiments to assess MAb binding. All but 3 of
the 12 mutants were expressed as wild-type GPC and were competent to mediate
cell-cell fusion. Mutations specifically included within the N-terminal G2-ecto
MBP fusion protein recognized by F100G5 are further described below.
MAb-mediated virus neutralization. A predetermined amount of JUNV Can-
did 1 virus was incubated with MAb in growth medium for 10 min, and the
mixture was then placed onto Vero cells for 8 h at 37°C. Final concentrations of
F100G5 and GB03-BE08 were 30 g/ml and 10 g/ml, respectively. Cells were
then washed, harvested with trypsin-EDTA (Invitrogen), and distributed to six-
well culture plates, where infection was allowed to proceed for an additional 16 h.
Cultures were then fixed with cold methanol-acetone (1:1), and the number of
infected (multicellular) foci was determined by immunohistochemical staining
using the nucleoprotein MAb NA05-AG12 (68), horseradish peroxidase-conju-
gated sheep anti-mouse secondary antibody, and diaminobenzidine substrate.
RESULTS
Monoclonal antibodies directed against the ectodomain of
G2. Recombinant forms of the G2 ectodomain of JUNV and
MACV (residues 255 to 417 and 266 to 428, respectively) (Fig.
1) were expressed in E. coli and purified by affinity chroma-
tography using an N-terminal 6His tag. JUNV and MACV are
two closely related pathogenic New World arenaviruses, and
the sequences included within the recombinant constructs
were 88% identical (with largely conservative amino acid
changes at other positions). Mice were immunized with the
recombinant proteins (referred to as JUNV G2* and MACV
G2*, respectively) and used to generate immunogen-specific
hybridomas (5) (Table 1).
MAb recognition of the authentic JUNV GPC was deter-
mined by Western blot analysis of JUNV-infected cells (Ro-
mero strain) (Table 1). Two of seven MAbs from JUNV G2*-
immunized mice (F100G4 and F100G5) and one of nine from
MACV G2*-immunized mice (F106G3) were able to recognize
JUNV GPC in this context.
Identification of the G2 six-helix bundle core. Ectopic ex-
pression of the class I virus fusion protein ectodomain in E. coli
typically yields insoluble peptide aggregates which must be
solubilized and refolded in vitro to attain a more native struc-
ture, that of the stable postfusion six-helix bundle (7, 57).
MAbs directed against this structure in other envelope glyco-
proteins have proven invaluable for studying structure-func-
tion relationships in membrane fusion (44, 46, 48, 55), and we
were interested to identify any such MAbs in our panel. Al-
though prior studies by Eschli and colleagues had demon-
strated that G2 can adopt an -helical trimeric structure com-
prising heterodimeric HR1 and HR2 sequences (33), we
sought to precisely define the extent of the six-stranded helical
structure so as to identify specific MAbs. The recombinant
peptide G2-151, comprising the JUNV G2 ectodomain without
the extreme N- and C-terminal regions (residues 264 to 414)
(Fig. 1), was expressed in E. coli and harvested as insoluble
inclusion bodies. G2-151 was solubilized using 8 M urea and
purified by reverse-phase chromatography as described in Ma-
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terials and Methods. Following air oxidation, to allow forma-
tion of a disulfide-bonded loop that typically separates HR1
and HR2 regions in class I fusion proteins, the protein was
subjected to refolding by stepwise dilution into PBS supple-
mented with 1.5 M GdmCl. In this buffer at a 10 M protein
concentration and 4°C, the CD spectrum of G2-151 exhibited
the characteristic signature of an -helical conformation, with
minima at 222 and 208 nm (data not shown). Sedimentation
equilibrium measurements revealed a concentration-depen-
dent apparent molecular weight and a systematic trend in the
residuals between the data and the linear fit, suggesting that
G2-151 tended to aggregate.
G2-151 becomes largely insoluble on complete removal of
GdmCl, and this protein aggregate was subjected to limited
proteolysis by trypsin or proteinase K in order to identify a
soluble protease-resistant core. This method of protein dissec-
tion has frequently been used to define the well-folded helical
substructure in class I virus fusion proteins (7, 20, 57). Both
proteases generated two similarly sized peptide fragments
from G2-151: trypsin digestion resulted in two predominant
fragments corresponding to residues 325 to 360 (36 amino
acids; denoted N36) and residues 382 to 417 (36 amino acids;
C36), whereas proteinase K digestion yielded two slightly
shorter fragments corresponding to residues 325 to 353 (N29)
and residues 382 to 411 (C30) (Fig. 1). The similarity between
fragments generated by each enzyme suggested a common
protease-resistant core structure. Because proteinase K is a
less specific protease than trypsin, the proteolytic fragments
N29 and C30 may more accurately delimit the core region.
This empirically determined core includes key residues previ-
ously identified by mutagenesis (75) and is somewhat offset
from the HR peptides described previously (33).
In isolation, neither the synthetic N29 nor the C30 peptide is
helical (Fig. 2A). C30 peptide displays little secondary struc-
ture in CD studies, and N29 shows a strong minimum at 227
nm, which is not typical of -helical signal. Although the ther-
mal unfolding transition of N29 was highly cooperative, the Tm
was low (	12°C at 100 M peptide concentration), and the
solution became turbid upon heating, indicating that the iso-
lated N29 peptide is not well structured and has a strong
tendency to aggregate. Importantly, however, an equimolar
mixture of the N29 and C30 peptides displayed a CD spectrum
diagnostic of an -helix, with characteristic minima at 222 and
208 nm (Fig. 2A). The []222 indicated greater than 90% helical
content at 4°C in PBS.
The stability of the -helical N29/C30 complex was assessed
by monitoring the change in []222 as a function of tempera-
ture. The thermal unfolding transition was cooperative and
reversible, with a Tm of 64°C at 100 M peptide concentration
in PBS (pH 7.0) (Fig. 2B). Sedimentation equilibrium experi-
ments indicated that the N29 and C30 peptides form a trimer
of heterodimers: the observed molecular mass 21.2 (kDa) was
consistent with the predicted molecular mass for a trimer of
6.95 kDa monomeric N29/C30 heterodimers (Fig. 2C). We
concluded that the N29 and C30 peptides associate to form a
discrete, stable -helical trimer of heterodimers, which closely
defines the extent of the six-helix bundle in the postfusion form
of JUNV GPC.
MAbs directed against postfusion forms of G2. Using the
N29/C30 peptides to form a six-helix bundle, we identified only
JUNV      AFFSWSLTDSSGKDTPGGYCLEEWMLVAAKMKCFGNTAVAKCNLNHDSEFCDMLRLFD..
MACV      AFFSWSLTDSSGKDMPGGYCLEEWMLIAAKMKCFGNTAVAKCNQNHDSEFCDMLRLFD..
GUAV      AFFSWSLSDPKGNDMPGGYCLERWMLVAGDLKCFGNTAVAKCNLNHDSEFCDMLRLFD..
TCRV      AFFSWSLTDPLGNEAPGGYCLEKWMLVASELKCFGNTAIAKCNQNHDSEFCDMLRLFD..
SABV      AFFSWTITDAVGNDMPGGYCLERWMLVTSDLKCFGNTALAKCNLDHDSEFCDMLKLFE.. 
CHPV      GVFTWTITDAAGNDMPGGYCLERWMLVTSDLKCFGNTALAKCNLNHDSEFCDMLKLFE..
LASV-JOS  GTFTWTLSDSEGKDTPGGYCLTRWMLIEAELKCFGNTAVAKCNEKHDEEFCDMLRLFD..
LCMV-ARM  GTFTWTLSDSSGVENPGGYCLTKWMILAAELKCFGNTAVAKCNVNHDAEFCDMLRLFD..
MOPV      GLFTWTLSDSEGNDMPGGYCLTRSMLIGMDLKCFGNTAIAKCNQKHDEEFCDMLRLFD..
PICV      GFFTWDLSDSSGQHVPGGYCLEQWAIVWAGIKCFDNTVMAKCNKDHNEEFCDTLRLFD..
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FIG. 1. Schematic representation of the JUNV G2 ectodomain and fusion peptide region. The amino acid sequence of the JUNV G2
ectodomain is shown on top, in text, and as a line drawing (residues 252 to 428; MC2 strain, accession number D10072). Small dots above the text
are spaced 10 amino acids apart, starting with position 260. The boxed sequences comprise peptides G2, G2-151, and G2-114 (see text). The
nominal start of the G2 transmembrane domain is indicated at residues 425 to 428. Cysteines are marked by vertical lines in the schematic, and
gray boxes represent HR1 and HR2, as defined by the N29 and C30 peptides (see text). The X marks the division between N- and C-terminal
regions in MBP fusion proteins, and arrowheads indicate alanine mutations used in this work. The positions chosen for mutation are identically
conserved or invariant in charge among arenaviruses. Below, fusion peptide sequences are compared among arenaviruses (JUNV residues 252 to
309). N-terminal and internal fusion peptide regions (N-FPS and I-FPS, respectively) are indicated and are based on the work of Klewitz et al. (50).
Conserved cysteines are highlighted in gray, and arrowheads represent the alanine mutations studied. Accession numbers for other arenavirus
glycoproteins are as follows: Machupo virus (MACV), AAT40455; Guanarito virus (GUAV), AAS55656; Tacaribe virus (TCRV), NP_694849;
Sabiá virus (SABV), YP_089665; Chapare virus (CHPV), YP_001816782; LASV-Jos, NP_694870; lymphocytic choriomeningitis virus ([LCMV]
LCMV-Arm), NP_694851; Mopeia virus (MOPV), YP_170709; and Pichinde virus (PICV), AAB58484.
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one MAb (F100G4) that recognized this structure in an ELISA
(Table 1). Because this MAb was also able to bind isolated C41
peptide (data not shown), we concluded that F100G4 is di-
rected against a linear rather than conformational epitope.
In the class I virus envelope glycoprotein, the soluble six-
helix bundle is part of a postfusion trimer-of-hairpins structure
that includes the disulfide-bonded hinge region between HR1
and HR2. To determine whether this loop is recognized by any
of the MAbs, we engineered a single peptide (G2-114) that
included HR1 and HR2 as well as the intervening amino acids
(residues 305 to 418). Upon refolding and oxidation, G2-114
was similar to G2-151 in -helical content yet, importantly,
remained soluble in PBS (data not shown). Thus, G2-114 likely
represents a soluble model for the JUNV trimer-of-hairpins
structure.
Using G2-114 as antigen in an ELISA, we identified three
additional MAbs (F100G1, F100G6, and F109G1) that recog-
nized the intervening region in the trimer-of-hairpins structure
(Table 1). As in other class I fusion proteins, this region likely
forms a disulfide-bonded loop in GPC. Consistent with this
notion, serine substitutions at C356 and/or C377 (Fig. 1) result
in severe misfolding of the mutant GPC (J. York and J. H.
Nunberg, unpublished data).
MAb F100G5 recognizes a pH-induced epitope on cells ex-
pressing GPC. Despite reactivity of some of the MAbs in
Western blotting and ELISA experiments, flow cytometry re-
vealed that none of the 16 MAbs was able to recognize JUNV
GPC expressed on the surface of transfected Vero cells (Table
1; Fig. 3A). GPC expression in these experiments was con-
firmed by using the well-characterized G1-directed MAb
GB03-BE08 (68, 81) (Fig. 3A) and by the ability of the cell
monolayers to form syncytia in response to acidic pH (81). The
failure of the G2 MAbs to detect GPC on the cell surface may
reflect a number of factors, including the likelihood that the
recombinant peptide immunogen contained predominantly
postfusion structures that would not be found in the prefusion
complex.
We therefore asked whether any of the MAbs might be able
to recognize the postfusion form of GPC on the cell surface. In
order to avoid syncytium formation in these experiments,
GPC-expressing cells were harvested and resuspended prior to
exposure to low-pH medium. In the absence of a monolayer of
abutting cells, membrane fusion in suspension is induced but
proceeds nonproductively. This process is irreversible, and pH
treatment of virions in the absence of target cells is known to
destroy infectivity (29). For flow cytometric analysis, after 10
min at low pH, the cell suspension was returned to neutral pH
by the addition of an excess of cold DPBS and then incubated
with MAb.
In contrast to its lack of reactivity with prefusion GPC, MAb
F100G5 was able to recognize a form of the protein arising
upon acidification (Fig. 3A). This new epitope might develop
through pH-induced structural changes in G2 or through ex-
posure of a previously sequestered region of the protein. Upon
neutralization, however, the epitope is stably expressed on the
inactivated GPC product. All other G2 MAbs again failed to
bind, including those that recognize postfusion determinants in
the peptide ELISA (F100G1, F100G4, F100G6, and F109G1).
The G1-directed MAb BE08 bound well to pH-treated cells,
with some reduction in maximal signal due to pH-induced
shedding of G1 from mature GPC (compared to coexisting
GPC precursor) on the cell surface (76).
Fusion competence is required for F100G5 binding. In order
to assess whether the newly presented F100G5 epitope arises
TABLE 1. Properties of monoclonal antibodies directed to the G2 ectodomains of JUNV and MACVa
Immunogen MAb MAb isotype Western blotreactivityb
ELISA result Flow cytometry result atd:
Six-helix bundle
peptidec G2-114 peptide Neutral pH pH 5.0
JUNV G2* F100G1 IgG1/
     
F100G2 IgG1/
     
F100G3 IgG1/
     
F100G4 IgG1/
     
F100G5 IgG1/
     
F100G6 IgG2a/
     
F109G1 IgG2b/
     
MACV G2* F106G1 IgG1/
     
F106G2 IgG1/
     
F106G3 IgG1/
     
F106G4 IgG2b/
     
F106G5 IgG2b/
     
F106G6 IgG2a/
     
F111G2 IgG1/
     
F111G3 IgG1/
     
F111G4 IgG1/
     
JUNV virione GB03-BE08 IgG2a/ND     
a Reactivity in all assays was scored relative to the maximal response in the panel of G2 MAbs, with semiquantitative quantiles reported as follows: from  (no
response) to , , , and  (maximal response).
b Reactivity to GPC in JUNV-infected cell lysates.
c Equimolar N29 and C30 peptides were mixed prior to coating plates for the ELISA.
d Selected histograms are shown in Fig. 3A.
e GB03-BE08 (68) recognizes G1 (81); the light chain was not determined (ND).
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along the conformational pathway leading to membrane fusion
or simply as an incidental consequence of exposure to acidic
pH, we examined formation of the epitope in several forms of
GPC that are specifically unable to promote membrane fusion.
A cleavage-defective GPC mutant in which the SKI-1/S1P
cleavage site has been altered is unable to mediate cell-cell
fusion (75) and, as shown in Fig. 3B, was unable to induce
F100G5 binding upon exposure to low pH. Similarly, the fu-
sion-defective K33A mutant, containing a mutation in SSP that
stabilizes the prefusion GPC complex against acidic pH (80),
was unable to generate the F100G5 epitope. Finally, incuba-
tion of wild-type GPC with the small-molecule fusion inhibitor
ST-294 (8), which binds to stabilize the prefusion GPC com-
plex against pH-induced activation (76), likewise prevented
exposure of the F100G5 epitope. Taken together, these results
indicate that formation of the F100G5 epitope is specific and
dependent on the ability of GPC to initiate membrane fusion
activity.
F100G5 prevents cell-cell fusion when present during acti-
vation. To further explore the relationship of the F100G5
epitope to the pH-induced structural changes leading to mem-
brane fusion, we asked whether F100G5 binding could inhibit
GPC-mediated syncytium formation. Specifically, we examined
the effect of F100G5 addition during each of three phases in
the cell-cell fusion assay (81): during the initial coculture of
GPC-expressing and target cells, during acidification at pH 5.0,
and upon subsequent incubation at neutral pH when cell-cell
fusion becomes evident. As a control, we also examined the
behavior of the virus-neutralizing G1-directed MAb GB03-
BE08 (68). GB03-BE08 binds to GPC-expressing cells at neu-
tral pH (81), and we predicted that inhibition of syncytium
formation by this MAb would require incubation prior to acid-
ification. Because F100G5 binding requires prior exposure to
low pH, we reasoned that if the MAb were to inhibit syncytium
formation it would do so only during the low-pH pulse.
The virus-neutralizing MAb GB03-BE08 was able to com-
pletely inhibit cell-cell fusion when added to the coculture
prior to acidification (Fig. 4). Only a small residuum of inhi-
bition remained when the MAb was added with the pH pulse,
possibly reflecting the relative rates of pH-induced activation
versus MAb binding. Incubation after the coculture was re-
turned to neutral pH had no effect on syncytium formation.
These findings suggest that the period of vulnerability to inhi-
bition by MAb GB03-BE08 had largely closed upon acidifica-
tion. This behavior is consistent with MAb binding to the
native, prefusion GPC complex in such a way as to prevent
pH-induced membrane fusion.
Interestingly, F100G5 was also able to inhibit syncytium
formation, but only when present during the low-pH pulse
(Fig. 4). Incubation with the MAb either before acidification or
after neutralization had no effect on cell-cell fusion. This result
is in keeping with the requirement for pH-induced activation
for F100G5 binding (Fig. 3A). Importantly, inhibition by
F100G5 indicates that the MAb targets an intermediate form
of GPC that is on-path to membrane fusion. Binding to an
off-path intermediate, or to a terminal postfusion structure,
would not be expected to interfere with syncytium formation.
FIG. 2. Solution properties of the N29/C30 complex. (A) CD spectra in PBS (pH 7.0) at 4°C and 100 M peptide concentration. (B) Thermal
melts monitored by CD at 222 nm. (C) Sedimentation equilibrium data for the N29/C30 complex (100 M) at 20°C and 22 krpm in PBS (pH 7.0).
The data fit closely to a trimeric complex. Curves expected for dimeric and tetrameric models are indicated for comparison. The deviation in the
data from the linear fit for a trimer is plotted (upper). (D) Helical wheel diagrams of the six-helix bundle. The antiparallel N and C helices are
drawn looking down toward the membrane. The register of the respective coils was assigned to maximize hydrophobicity at interhelical a and d
positions.
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F100G5 binds at or near the N terminus of G2. To better
understand the nature of the F100G5 epitope, we sought to
define amino acid sequences required for binding. For these
studies, we took advantage of the reactivity of F100G5 in
Western blot analysis. As the MAb recognizes authentic G2 in
lysates of JUNV-infected cells (Table 1) and in GPC-express-
ing Vero cells (see Fig. 6, below), we found that F100G5 also
binds an E. coli-expressed fusion protein containing the G2
ectodomain (residues 252 to 424) appended to the C terminus
of MBP. Despite the susceptibility of the MBP fusion protein
to proteolytic degradation (Fig. 5), full-length molecules were
detectible by protein staining of the affinity-purified protein in
SDS-PAGE (left panel) and were clearly recognized by MAb
F100G5 (right panel). Binding does not require that GPC be
glycosylated.
Based on this reactivity with recombinant protein, we further
partitioned the G2 ectodomain to generate fusion proteins
containing either the N- or C-terminal regions (residues 252 to
316 or 317 to 424, respectively). The larger C-terminal con-
struct included both HR1 and HR2. Western blot analysis of
the purified fusion proteins showed that MAb F100G5 recog-
nized only the N-terminal portion of G2 (Fig. 5, right). Thus,
FIG. 4. MAb F100G5 inhibits cell-cell fusion when added on ex-
posure to acidic pH. Cells expressing wild-type GPC were incubated
with MAb GB03-BE08 (left; 10 g/ml) or F100G5 (right; 30 g/ml)
either during the initial coculture with target cells at neutral medium
(pre), during acidification at pH 5.0 (pH 5), or upon the return of the
culture to neutral medium, in which cell-cell fusion becomes manifest
(post) (81). Syncytium formation was reported by expression of -ga-
lactosidase and quantitated by chemiluminescence (in relative light
units [RLU]). Error bars represent 1 standard deviation among qua-
druplicate wells. Missing bars were not rendered at the scale of the
graph. The experiment shown is representative of five independent
repetitions.
FIG. 3. Flow cytometric analysis of MAb binding to cell surface GPC. (A) Selected MAbs were incubated with Vero cells expressing wild-type
(wt) JUNV GPC that had been exposed to neutral pH (gray histogram) or to pH 5.0 (black line histogram). The MAb (and secondary antibody)
used is shown below each histogram. Abbreviations: GAMFITC, fluorescein isothiocyanate-conjugated goat anti-mouse secondary antibody; BE08,
MAb GB03-BE08. (B) MAb F100G5 was incubated with cells expressing wt or mutant GPC that had been exposed to neutral pH (gray histogram)
or to pH 5.0 (black line histogram). Mutants are cleavage-defective (cd GPC [81]), K33A GPC (80), and K283A GPC (see text).  ST-294 indicates
that cells expressing wt GPC were first incubated with a 50 M concentration of the small-molecule fusion inhibitor ST-294 (8, 76) prior to
exposure to neutral or acidic pH.
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binding requires sequences that lie between the N terminus of
G2 and the region upstream of HR1. The failure of F100G5 to
bind the C-terminal portion of the G2 ectodomain is consistent
with its inability to recognize the six-helix bundle and G2-114
peptides in ELISA (Table 1).
Further mapping of the F100G5 epitope made use of a panel
of GPC mutants. Eight highly conserved positions in the N-
terminal portion of GPC (D260, K283, K292, H297, E300,
D303, R306, and D309) were replaced with alanine, and the
mutant proteins were expressed in Vero cells. Of the eight
mutants, all but two were efficiently assembled, processed, and
transported to the cell surface; E300A and D303A were mis-
folded and remained in the endoplasmic reticulum (York and
Nunberg, unpublished). The properly folded mutants were also
able to promote cell-cell fusion at levels comparable to wild-
type GPC (80 to 160% of wild-type activity) (data not shown).
Only D309A was somewhat debilitated (30% of wild-type ac-
tivity). Nonetheless, all eight GPC mutants were expressed well
(Fig. 6) and could be used to evaluate recognition by F100G5
in Western blot analysis. Of the mutants, only K283A GPC was
significantly reduced in its reactivity with F100G5 (Fig. 6). As
anticipated, MAb F100G1, which recognized the trimer-of-
hairpins structure in the G2-114 peptide (Table 1), bound
equally to all the N-terminal GPC mutants. This finding also
confirms that the reduction in F100G5 binding to K283A was
not due to differences in the level of protein expression. Rec-
ognition by another MAb, F106G3, was highly dependent on
positions H297, E300, and D303 (Fig. 6). Although this MAb
was originally derived from MACV G2*, this span of amino
acids is identically conserved in JUNV GPC. Indeed, MAb
F106G3 recognized all other JUNV mutants, including K283A,
as strongly as the wild type. Taken together, these findings
demonstrate that MAb F100G5 binding is dependent on the
K283 side chain located near the N terminus of G2. Consistent
with this conclusion, binding of F100G5 to the pH-induced
form of the K283A GPC on the cell surface was also abolished
(Fig. 3B). Interestingly, GPC of the related Tacaribe virus
(TCRV), which differs from JUNV at three positions immedi-
ately N-terminal to K283 (Fig. 1), was not bound by F100G5,
whereas MACV GPC, which is identical to JUNV at these
positions, is recognized (data not shown). These observations
suggest that the F100G5 epitope may include the three adja-
cent residues (A280, K281, and M282). The MAb F106G3
appears to bind an epitope 15 to 20 residues C-terminal to
F100G5.
DISCUSSION
In this report, we describe a MAb that recognizes a pH-
induced intermediate form of GPC so as to disrupt the con-
formational cascade leading to membrane fusion. The MAb
F100G5 epitope is not present in the prefusion GPC complex,
but rather forms upon pH-induced activation and prior to the
completion of cell-cell fusion. Bracketing formation of the
F100G5 binding site along the fusion reaction pathway focuses
attention on the complex series of on-path intermediates that
enable the productive completion of membrane fusion.
Exposure of the fusion peptide provides a target for fusion
inhibition. One clue to the placement of the F100G5-defined
intermediate along the pathway of GPC-mediated membrane
fusion, and the mechanism of fusion inhibition, derives from
our finding that F100G5 binds at or near the N terminus of G2,
a region that typically contains the envelope glycoprotein fu-
sion peptide. In the well-accepted model for membrane fusion
by class I virus proteins (30, 45, 73), the N-terminal fusion
peptide is sequestered in the prefusion state (19) and, upon
activation, is inserted into the target-cell membrane via a
“spring-loaded” mechanism (16). Collapse of the prehairpin
intermediate relocates the fusion peptide to the membrane-
proximal base of the postfusion six-helix bundle structure,
bringing the virus and target cell membranes into apposition
(13, 16, 56). While fusion of the lipid bilayers is energetically
coupled to formation of the stable six-helix bundle, the mech-
anism whereby the respective membranes are destabilized for
fusion is unclear. In this context, binding of F100G5 near the
G2 fusion peptide (50) might be envisioned to prevent inser-
tion of the fusion peptide into the target cell membrane, or to
interfere with the subsequent collapse of the prehairpin inter-
mediate.
FIG. 6. Mapping the F100G5 epitope using GPC mutants. Vero
cells expressing the indicated wild-type (wt) or alanine mutant GPC
were solubilized using 1% Triton X-100, and proteins were resolved by
SDS-PAGE and detected by Western blot analysis using the indicated
MAbs. MAb F100G1 recognizes the C-terminal trimer-of-hairpins
structure and thus serves to control for potential differences in expres-
sion among the mutants. Only the uncleaved G1-G2 precursor is
shown, to simplify the analysis of MAb binding; the mature G2 subunit
is less abundant, and staining intensity varies depending on the extent
of proteolytic maturation in each mutant.
FIG. 5. Western blot analysis of F100G5 binding to MBP fusion
proteins. Sequences encoding the entire ectodomain of JUNV G2
(G2ecto; residues 252 to 424), the N-terminal region (N-term; residues
252 to 316), or the C-terminal region (C-term; residues 317 to 424)
were appended to the C terminus of MBP, and the recombinant fusion
proteins were expressed in E. coli. Affinity-purified proteins were re-
solved by SDS-PAGE and detected by using Sypro Red protein stain
(left) or by Western blot analysis using MAb F100G5 (right). The
fusion proteins were proteolytically unstable, and the major band de-
tected by protein staining is the stable MBP core (MBP); the full-
length fusion proteins are visible in decreasing order of molecular mass
(62, 55, and 50 kDa). F100G5 binds only to the full-length proteins and
to proteolytic fragments of G2-ecto. Molecular mass markers are in-
dicated in kilodaltons.
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For fusion inhibition to occur, MAb F100G5 must bind
within the time frame of the pH-induced structural changes. If
the fusion peptide is only transiently exposed in productive
membrane fusion, then the time window for F100G5 binding is
even shorter. Single-particle measurements of influenza virus
fusion with defined lipid bilayers have shown that the initial
merger of the outer membrane leaflets (hemifusion) occurs
within 15 to 20 s of exposure to low pH at 23°C and can be
kinetically modeled to comprise three intermediate steps (35).
Transition to a stable fusion pore, in which both layers of the
membranes have fully coalesced, follows with a half-life of
roughly 2 s. In contrast, HIV Env-mediated membrane fusion
in cells takes place over the course of 15 to 60 min at 37°C (37,
41, 66), and the prehairpin intermediate can be operationally
trapped at temperatures below 23°C (60, 61). The extended
lifetime of the HIV prehairpin intermediate may be critical for
C-peptide binding and its inhibition of HIV entry (18, 36, 57,
60, 66, 74). These microscopic measurements of overt fusion
subsume multiple events and thus provide only a lower limit on
the rates of conformational changes in the envelope glycopro-
tein. While the time frame for membrane fusion by GPC is not
known, syncytium formation is readily induced by short expo-
sure to acidic pH (5 min) and proceeds well at 23°C (York and
Nunberg, unpublished). These observations suggest that GPC-
mediated membrane fusion may share elements with the pH-
induced process in HA.
The internal fusion peptide of GPC. In the prototypic class
I virus fusion proteins (influenza HA, HIV Env), the fusion
peptide is located at the N terminus of the fusion subunit and
comprises a hydrophobic region of variable length and se-
quence (15 to 25 amino acids) (recently reviewed in reference
23). In contrast, the N-terminal sequence of JUNV G2 con-
tains only short hydrophobic regions that are interspersed with
charged residues and is thus not readily identified as a proto-
typic fusion peptide (Fig. 1). Nonetheless, scanning mutagen-
esis by Klewitz and colleagues (50) has identified positions in
the N-terminal region of the LASV G2 that define a putative
fusion peptide. Key amino acids were shown to cluster in a
short N-terminal sequence (residues 252 to 258 in JUNV) as
well as in a neighboring internal region (residues 268 to 290).
Internal fusion peptide regions have also been described in
other class I proteins, such as the Ebola virus glycoprotein (72)
and the avian sarcoma/leukosis virus (ASLV) Env (25, 27, 39).
The K283 position recognized by MAb F100G5 lies within the
internal fusion peptide domain of JUNV and is conserved
among all arenaviruses.
Also invariant in the arenavirus fusion peptide is an array of
four cysteine residues (C271, C284, C293, and C302) that to-
gether point to the potential for disulfide bonding. In LASV
GPC (50), a deficiency engendered by the C292A mutation
(homologous to JUNV C284) is consistent with global misfold-
ing of the protein that arises as a consequence of an unpaired
cysteine. While the pattern of connectivity among the six in-
variant cysteines in the G2 ectodomain is unknown, it is likely
that the two cysteines between HR1 and HR2 (C356 and
C377) form the disulfide-bonded loop region commonly found
in class I fusion proteins. This implies that the four cysteine
side chains at the N terminus of G2 are available to form a
tight disulfide-bonded loop structure in the internal fusion
peptide. This putative architecture is distinct from the linear
N-terminal fusion peptides of HA and Env, but perhaps similar
to the disulfide-bonded internal fusion peptides found in Ebola
virus (72) and ASLV (25, 27, 39) glycoproteins. Structural
constraints imposed through disulfide bonding may facilitate
membrane insertion of the fusion peptide or its role in desta-
bilizing the apposed membranes for fusion.
Interestingly, the fusion peptides of so-called class II and
class III fusion proteins (e.g., of flaviviruses [10] and rhabdovi-
ruses [67], respectively) are also presented as disulfide-bonded
loops, albeit they are formed at the tips of anti-parallel -sheet
structures internal to the protein. Much as the recently de-
scribed class III fusion proteins appear to contain postfusion
structural elements of both class I and class II proteins (re-
cently reviewed in references 3 and 73), the internal fusion
peptides of certain class I proteins may share a constrained
loop structure with those of the other classes. Many of these
internal fusion peptides, including that of GPC (Fig. 1), con-
tain a central proline residue that has been suggested to intro-
duce a reverse turn into the disulfide-bonded loop (26).
Because fusion peptides have not been directly observed par-
ticipating in membrane fusion, the structural basis for fusion
peptide function is not well understood.
Virus neutralization in the endosome. As expected, F100G5
was unable to inhibit virus infection in cell culture. Incubation
of the attenuated Candid 1 isolate of JUNV (4, 58) with 30
g/ml of F100G5 had no effect on the number of infected cell
foci (data not shown). In contrast, virus neutralization using
MAb GB03-BE08, which binds G1 in the prefusion GPC com-
plex, was essentially complete. Based on the size of the endo-
cytic vesicle (diameter, 100 nm [49]), one can calculate that
only a small fraction of virus-containing vesicles will capture
F100G5 by passive fluid-phase endocytosis. For instance, in
100 g/ml of F100G5, fewer than one in five endocytic vesicles
will contain even one immunoglobulin molecule. If the volume
of the endocytosed virion is considered (diameter of also 100
nm), this fraction is greatly reduced. Therefore, antiviral activ-
ity in the endosome is essentially precluded for MAbs that do
not recognize the native virion particle. This observation sug-
gests that one might be able to increase the antiviral potency of
F100G5 by engineering bifunctional reagents that also bind to
the virion, or to nascent endosomal patches on the cell surface
(42). While F100G5 is not an immediate candidate for use in
antiviral intervention, structures identified by the MAb at or
near the G2 fusion peptide may serve as viable targets for
small-molecule compounds that effectively enter the endo-
some.
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